Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes

JAMA Oncol. 2020 Apr 1;6(4):589-590. doi: 10.1001/jamaoncol.2020.0065.

Authors

Benoît Rousseau¹, Joana Vidal^{1

2}, Luis A Diaz Jr¹

Affiliations

¹ Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
² Medical Oncology Department, Hospital del Mar Medical Research Institute, Centro de Investigación Biomédica en Red Cáncer, Instituto de Salud Carlos III, Barcelona, Spain.

PMID: 32134429
DOI: 10.1001/jamaoncol.2020.0065

No abstract available

Publication types

Letter
Comment

MeSH terms

Biomarkers
DNA Polymerase III / genetics
Humans
Immune Checkpoint Inhibitors*
Immunotherapy
Mutation
Neoplasms*
Treatment Outcome

Substances

Biomarkers
Immune Checkpoint Inhibitors
POLD1 protein, human
DNA Polymerase III